CompletedNCT04787302

Brain receptor activity after oral CVL-231

About this title

Medication studyAges 18–55United States + BelgiumSchizophrenia

The study in practice

Understand this study

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations: Boston and 1 more locationSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateStarted: June 1, 2021

Recruitment status: Completed
Enrollment listed in the registry: 15
Sponsor: Cerevel Therapeutics, LLC
Sponsor type: Biotech company
Study type: Drug
Intervention type: Drug
Study phase: Phase 1
Locations: United States, Belgium
Age range: From 18 Years to 55 Years
Official registry ID: NCT04787302
Official title: Show the full official title
A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Single Oral Doses Using Positron Emission Tomography in Healthy Adult Subjects

Completed

Boston, United States · Leuven, Belgium

FAQ

Who is behind this study?

The study sponsor is Cerevel Therapeutics, LLC.

Did this study involve medication?

Yes. The study involved medication, including CVL-231.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.